Developer docs
API playgroundTry for free, no card

Search company profiles

Hyperion Biosystems

Full company profile

uuid0000rmc

Namestring
Hyperion Biosystems
Legal namestring
Hyperion Biosystems
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Hyperion Biosystems is a privately held diagnostic technology company founded in 2013 as an MIT 'Tough Tech' spinout (originally C2Sense, Inc.) and headquartered at 500 Arsenal St, Watertown, Massachusetts. The company develops diagnostic hardware and software that combine computer vision with proprietary physics-based and AI-enhanced algorithms to improve the sensitivity and specificity of rapid diagnostic assays. Its primary commercial platform, HALO, is a low-cost, fully connected reader system that integrates into partners' existing point-of-care and at-home testing products to identify false positives, delineate non-specific binding, and mitigate assay defects without requiring assay redesign — the company cites an average 10x sensitivity enhancement across more than 10,000 assays run on its algorithms. In January 2026, the company announced Helios, a rapid molecular diagnostic platform leveraging padlock probe chemistry, isothermal amplification, and optical readout to detect hundreds to thousands of targets simultaneously at single-copy sensitivity in under three hours using standard laboratory equipment.

The company's business model is B2B enterprise technology licensing and integration: Hyperion works directly with leaders in the point-of-care and at-home testing markets through direct enterprise sales, licensing its algorithms and HALO reader hardware, providing custom algorithm/professional services, and (more recently) licensing its time-gated luminescence on-dose authentication technology into the pharmaceutical supply chain via a partnership with Colorcon. Revenue streams include technology licensing/royalties, HALO reader hardware sales, and algorithm and software services. The company has secured non-dilutive support via two NIH RADx Tech awards (2022 and 2023) for the HALO platform, an $8M Series B in January 2023, additional equity funding through 2025, and partnerships with Princeton BioMeditech (OTC COVID/Flu at-home reader) and Colorcon (anti-counterfeiting). Customers and partners publicly named include Hycor Biomedical, Princeton BioMeditech, and Colorcon. The leadership team comprises CEO Jason Cox, Ph.D., CTO Robert Deans, Ph.D., and CSO Eric Keller, with a board that includes Dr. Michael Mina (MD/PhD), former Walgreens CMO Dr. Kevin Ban (Strategic Advisor), Jim Mahoney, Adam Behrens Ph.D., and Andrew Weber.

Short descriptiontext

Hyperion Biosystems is an MIT spinout that builds computer vision and physics-based diagnostic readers and algorithms to improve sensitivity and specificity of point-of-care and at-home tests for diagnostic and pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diagnostic devices, molecular diagnostics, computer vision algorithms, point-of-care testing, anti-counterfeiting technology
Industry3 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Diagnostic Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Licensing proprietary diagnostic enhancement technology to diagnostic companies. Examples include licensing agreements with pharmaceutical partners for anti-counterfeiting technology.

hyperionbiosystems.com
2Hardware Sales - HALO Reader
TypeHardware Sales
Description

Sale of HALO diagnostic reader devices to partner companies for integration with their rapid diagnostic assays.

hyperionbiosystems.com
3Algorithm and Software Services
TypeProfessional Services
Description

Providing custom algorithm solutions to enhance existing diagnostic platforms without requiring partners to divert resources or redesign their assays.

hyperionbiosystems.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Halo
Description

A low cost, fully connected reader system for rapid diagnostic assays that simultaneously boosts sensitivity and specificity by leveraging physics-based, AI-enhanced algorithms. Identifies false positives, delineates non-specific binding and mitigates assay defects.

hyperionbiosystems.com
+1 more record
Core offering1 text field

Hyperion Biosystems designs and sells diagnostic devices and proprietary software that use computer vision and physics-based, AI-enhanced algorithms to improve the sensitivity and specificity of rapid diagnostic assays. The company partners with leaders in point-of-care and at-home testing markets to integrate its HALO diagnostic reader and algorithm platform into existing diagnostic offerings without requiring assay redesign, while also licensing on-dose anti-counterfeiting authentication technology for pharmaceutical and nutraceutical products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 10x average sensitivity enhancement through HALO platform
+3 more records
Product overview1 text field

Hyperion Biosystems offers a suite of diagnostic technologies organized as two distinct core platforms. Halo is a low-cost, fully connected reader system for rapid diagnostic assays that uses physics-based, AI-enhanced algorithms to boost sensitivity and specificity. Helios is a next-generation rapid molecular diagnostic platform designed for highly multiplexed target detection at single-copy sensitivity. Both platforms leverage computer vision and physics-based algorithms as core enabling technologies, with Helios additionally utilizing padlock probe chemistry and isothermal amplification. The company works with leaders in point-of-care and at-home testing markets to improve diagnostic sensitivity and specificity.

Product and service2 records
1HALO
CategoryDiagnostic Reader Hardware
Description

HALO is a low-cost, fully connected diagnostic reader system for rapid diagnostic assays. It uses a suite of physics-based, AI-enhanced algorithms to identify false positives, delineate non-specific binding, and mitigate assay defects, delivering higher assay performance without requiring redesign. It is sold to diagnostic companies for integration with their existing rapid diagnostic assays in point-of-care and at-home testing markets.

2Helios
CategoryMolecular Diagnostic Platform
Description

Helios is a rapid molecular diagnostic platform that enables simultaneous detection of hundreds to thousands of targets at single-copy sensitivity levels in less than three hours using standard laboratory equipment. It harnesses padlock probe chemistry, isothermal amplification, and an optical readout, and is intended for use by diagnostic and research laboratories.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-05-13
Description

Licensing agreement with Colorcon to commercialize and market a jointly-developed anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products. Hyperion's technology enables on-dose authentication using low-cost CMOS cameras and delayed emission materials.

Strategic tierMinorTypeOthersAnnounced on2024-06-01
Description

Dr. Kevin Ban, former Chief Medical Officer of Walgreens, joins Hyperion Biosystems Board of Directors as Strategic Advisor effective June 1, 2024.

3Michael Mina
Strategic tierMinorTypeOthersAnnounced on2024-05-24
Description

Dr. Michael Mina, MD, Ph.D. joins the Board of Directors as an independent director effective May 24, 2024.

hyperionbiosystems.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-16
Description

Partnership with Princeton BioMeditech to advance a digitally connected at-home diagnostic reader for sensitivity enhancement of OTC COVID-19/Flu A&B antigen tests. Received NIH RADx Tech funding to accelerate commercialization of PBM's Status COVID-19/Flu test used with C2Sense's Halo diagnostic reader. A second NIH RADx award was secured in April 2024 to continue the collaboration.

5Jim Mahoney
Strategic tierMinorTypeOthersAnnounced on2023-01-31
Description

Jim Mahoney, MBA, MMA appointed as independent director to the Board of Directors effective January 31, 2023.

hyperionbiosystems.com
6Adam Behrens
Strategic tierMinorTypeOthersAnnounced on2023-01-31
Description

Adam Behrens, Ph.D. joined the Board of Directors as an independent director effective January 31, 2023.

hyperionbiosystems.com
7Andrew Weber
Strategic tierMinorTypeOthersAnnounced on2023-01-31
Description

The Honorable Andrew Weber appointed to the Board of Directors effective January 31, 2023.

hyperionbiosystems.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

BioFire (owned by bioMérieux) is a market leader in multiplex molecular diagnostics through its FilmArray panels. Comparable to Hyperion's Helios platform in targeting syndromic and high-multiplex molecular testing at point-of-care, though BioFire is a much larger incumbent with FDA-cleared panels already deployed across hospital networks.

TypeDirect peer
Description

Visby Medical develops rapid PCR-based point-of-care diagnostics for infectious disease. Comparable to Hyperion in targeting rapid, single-use molecular diagnostics outside traditional lab settings, with overlapping customer profiles in OTC and point-of-care testing markets served by HALO and Helios.

TypeDirect peer
Description

Quanterix builds ultra-sensitive single-molecule detection platforms (Simoa) used in research and clinical diagnostics. Comparable to Hyperion's focus on sensitivity enhancement and single-copy detection, particularly Helios's claimed single-copy sensitivity, though Quanterix addresses protein biomarkers versus Helios's nucleic-acid targets.

TypeBroad incumbent
Description

Cepheid (owned by Danaher) is the established leader in automated molecular diagnostics with its GeneXpert system. Comparable to Hyperion in the molecular diagnostics space where Helios competes, but Cepheid operates at much larger scale with broad installed base across hospitals and reference labs.

TypeDirect peer
Description

T2 Biosystems develops diagnostic instruments (T2MR) for direct-from-sample molecular detection without sample prep. Comparable to Hyperion as a small-cap diagnostic instrument company focused on novel detection methods (magnetic resonance vs. Hyperion's optical/computer vision approach), serving similar hospital and clinical lab customers.

TypeBroad incumbent
Description

GenMark (now part of Roche) developed the ePlex system for multiplex molecular diagnostics at hospital point-of-care. Directly comparable to Hyperion's Helios in multiplex syndromic testing approach, but operates as part of a much larger diagnostics organization with broader assay menus and global reach.

TypeDirect peer
Description

Quantum-Si is developing next-generation protein sequencing platforms with single-molecule sensitivity. Comparable to Hyperion as a small-cap next-generation diagnostic platform company focused on ultra-sensitive detection, though Quantum-Si's technology targets proteomics rather than the molecular diagnostics space Helios addresses.

TypeEmerging player
Description

Opentrons provides accessible lab automation and is expanding into diagnostic workflows including COVID testing. Comparable to Hyperion as a smaller player targeting democratization of advanced diagnostics through affordable hardware and software, with some overlap in addressing the OTC and point-of-care testing markets.

TypeDirect peer
Description

Mesa Labs develops and manufactures quality assurance instruments and diagnostic tools including biological indicators and sterility assurance products. Comparable to Hyperion in operating as a specialty diagnostic instruments company with B2B sales to manufacturers and clinical end users, though Mesa has a much more diversified product portfolio.

TypeEmerging player
Description

Paige applies AI/computer vision to pathology and cancer diagnostics. Comparable to Hyperion in leveraging computer vision and AI to improve diagnostic accuracy beyond what conventional readers achieve, though Paige focuses on digital pathology image interpretation versus Hyperion's assay-result interpretation.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hyperion Biosystems

Diagnostic Deviceshyperionbiosystems.com

Hyperion Biosystems is an MIT spinout that builds computer vision and physics-based diagnostic readers and algorithms to improve sensitivity and specificity of point-of-care and at-home tests for diagnostic and pharmaceutical partners.

What Hyperion Biosystems does

Hyperion Biosystems is a privately held diagnostic technology company founded in 2013 as an MIT 'Tough Tech' spinout (originally C2Sense, Inc.) and headquartered at 500 Arsenal St, Watertown, Massachusetts. The company develops diagnostic hardware and software that combine computer vision with proprietary physics-based and AI-enhanced algorithms to improve the sensitivity and specificity of rapid diagnostic assays. Its primary commercial platform, HALO, is a low-cost, fully connected reader system that integrates into partners' existing point-of-care and at-home testing products to identify false positives, delineate non-specific binding, and mitigate assay defects without requiring assay redesign — the company cites an average 10x sensitivity enhancement across more than 10,000 assays run on its algorithms. In January 2026, the company announced Helios, a rapid molecular diagnostic platform leveraging padlock probe chemistry, isothermal amplification, and optical readout to detect hundreds to thousands of targets simultaneously at single-copy sensitivity in under three hours using standard laboratory equipment.

The company's business model is B2B enterprise technology licensing and integration: Hyperion works directly with leaders in the point-of-care and at-home testing markets through direct enterprise sales, licensing its algorithms and HALO reader hardware, providing custom algorithm/professional services, and (more recently) licensing its time-gated luminescence on-dose authentication technology into the pharmaceutical supply chain via a partnership with Colorcon. Revenue streams include technology licensing/royalties, HALO reader hardware sales, and algorithm and software services. The company has secured non-dilutive support via two NIH RADx Tech awards (2022 and 2023) for the HALO platform, an $8M Series B in January 2023, additional equity funding through 2025, and partnerships with Princeton BioMeditech (OTC COVID/Flu at-home reader) and Colorcon (anti-counterfeiting). Customers and partners publicly named include Hycor Biomedical, Princeton BioMeditech, and Colorcon. The leadership team comprises CEO Jason Cox, Ph.D., CTO Robert Deans, Ph.D., and CSO Eric Keller, with a board that includes Dr. Michael Mina (MD/PhD), former Walgreens CMO Dr. Kevin Ban (Strategic Advisor), Jim Mahoney, Adam Behrens Ph.D., and Andrew Weber.

Hyperion Biosystems firmographics

Firmographics
Name
Hyperion Biosystems
Legal name
Hyperion Biosystems
Website
https://hyperionbiosystems.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Hyperion Biosystems is an MIT spinout that builds computer vision and physics-based diagnostic readers and algorithms to improve sensitivity and specificity of point-of-care and at-home tests for diagnostic and pharmaceutical partners.
Ownership category
akta.pro rank

Hyperion Biosystems industry classification

Industry
Product category
Diagnostic Devices
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Diagnostic devices
  • Molecular diagnostics
  • Computer vision algorithms
  • Point-of-care testing
  • Anti-counterfeiting technology

Where Hyperion Biosystems is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Hyperion Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing: Licensing proprietary diagnostic enhancement technology to diagnostic companies. Examples include licensing agreements with pharmaceutical partners for anti-counterfeiting technology.
  2. Hardware Sales - HALO Reader: Sale of HALO diagnostic reader devices to partner companies for integration with their rapid diagnostic assays.
  3. Algorithm and Software Services: Providing custom algorithm solutions to enhance existing diagnostic platforms without requiring partners to divert resources or redesign their assays.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Hyperion Biosystems product offering

Product offering

Core offering

Hyperion Biosystems designs and sells diagnostic devices and proprietary software that use computer vision and physics-based, AI-enhanced algorithms to improve the sensitivity and specificity of rapid diagnostic assays. The company partners with leaders in point-of-care and at-home testing markets to integrate its HALO diagnostic reader and algorithm platform into existing diagnostic offerings without requiring assay redesign, while also licensing on-dose anti-counterfeiting authentication technology for pharmaceutical and nutraceutical products.

Product overview

Hyperion Biosystems offers a suite of diagnostic technologies organized as two distinct core platforms. Halo is a low-cost, fully connected reader system for rapid diagnostic assays that uses physics-based, AI-enhanced algorithms to boost sensitivity and specificity. Helios is a next-generation rapid molecular diagnostic platform designed for highly multiplexed target detection at single-copy sensitivity. Both platforms leverage computer vision and physics-based algorithms as core enabling technologies, with Helios additionally utilizing padlock probe chemistry and isothermal amplification. The company works with leaders in point-of-care and at-home testing markets to improve diagnostic sensitivity and specificity.

Differentiator

Problem solved

Functional benefit

Brands

  • Halo: A low cost, fully connected reader system for rapid diagnostic assays that simultaneously boosts sensitivity and specificity by leveraging physics-based, AI-enhanced algorithms. Identifies false positives, delineates non-specific binding and mitigates assay defects.
  • Helios

Products and services

  • HALO HALO is a low-cost, fully connected diagnostic reader system for rapid diagnostic assays. It uses a suite of physics-based, AI-enhanced algorithms to identify false positives, delineate non-specific binding, and mitigate assay defects, delivering higher assay performance without requiring redesign. It is sold to diagnostic companies for integration with their existing rapid diagnostic assays in point-of-care and at-home testing markets.
  • Helios Helios is a rapid molecular diagnostic platform that enables simultaneous detection of hundreds to thousands of targets at single-copy sensitivity levels in less than three hours using standard laboratory equipment. It harnesses padlock probe chemistry, isothermal amplification, and an optical readout, and is intended for use by diagnostic and research laboratories.

Quantifiable outcome

  • 10x average sensitivity enhancement through HALO platform
  • +3 more outcomes

Companies that use Hyperion Biosystems

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Hyperion Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Hyperion Biosystems partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • ColorconcoreOEM/ Whitelabel/ Licensing Partner · 13 May 2025Licensing agreement with Colorcon to commercialize and market a jointly-developed anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products. Hyperion's technology enables on-dose authentication using low-cost CMOS cameras and delayed emission materials.
  • Kevin BanminorOthers · 1 June 2024Dr. Kevin Ban, former Chief Medical Officer of Walgreens, joins Hyperion Biosystems Board of Directors as Strategic Advisor effective June 1, 2024.
  • Michael MinaminorOthers · 24 May 2024Dr. Michael Mina, MD, Ph.D. joins the Board of Directors as an independent director effective May 24, 2024.
  • Princeton BioMeditechcoreStrategic or Co-development Partner · 16 May 2023Partnership with Princeton BioMeditech to advance a digitally connected at-home diagnostic reader for sensitivity enhancement of OTC COVID-19/Flu A&B antigen tests. Received NIH RADx Tech funding to accelerate commercialization of PBM's Status COVID-19/Flu test used with C2Sense's Halo diagnostic reader. A second NIH RADx award was secured in April 2024 to continue the collaboration.
  • Jim MahoneyminorOthers · 31 January 2023Jim Mahoney, MBA, MMA appointed as independent director to the Board of Directors effective January 31, 2023.
  • Adam BehrensminorOthers · 31 January 2023Adam Behrens, Ph.D. joined the Board of Directors as an independent director effective January 31, 2023.
  • Andrew WeberminorOthers · 31 January 2023The Honorable Andrew Weber appointed to the Board of Directors effective January 31, 2023.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Hyperion Biosystems competitors and assessment

Company assessment

Broad incumbents

  • BioFire Diagnostics (bioMérieux): BioFire (owned by bioMérieux) is a market leader in multiplex molecular diagnostics through its FilmArray panels. Comparable to Hyperion's Helios platform in targeting syndromic and high-multiplex molecular testing at point-of-care, though BioFire is a much larger incumbent with FDA-cleared panels already deployed across hospital networks.
  • Cepheid (Danaher): Cepheid (owned by Danaher) is the established leader in automated molecular diagnostics with its GeneXpert system. Comparable to Hyperion in the molecular diagnostics space where Helios competes, but Cepheid operates at much larger scale with broad installed base across hospitals and reference labs.
  • GenMark Diagnostics (Roche): GenMark (now part of Roche) developed the ePlex system for multiplex molecular diagnostics at hospital point-of-care. Directly comparable to Hyperion's Helios in multiplex syndromic testing approach, but operates as part of a much larger diagnostics organization with broader assay menus and global reach.

Direct peers

  • Visby Medical: Visby Medical develops rapid PCR-based point-of-care diagnostics for infectious disease. Comparable to Hyperion in targeting rapid, single-use molecular diagnostics outside traditional lab settings, with overlapping customer profiles in OTC and point-of-care testing markets served by HALO and Helios.
  • Quanterix: Quanterix builds ultra-sensitive single-molecule detection platforms (Simoa) used in research and clinical diagnostics. Comparable to Hyperion's focus on sensitivity enhancement and single-copy detection, particularly Helios's claimed single-copy sensitivity, though Quanterix addresses protein biomarkers versus Helios's nucleic-acid targets.
  • T2 Biosystems: T2 Biosystems develops diagnostic instruments (T2MR) for direct-from-sample molecular detection without sample prep. Comparable to Hyperion as a small-cap diagnostic instrument company focused on novel detection methods (magnetic resonance vs. Hyperion's optical/computer vision approach), serving similar hospital and clinical lab customers.
  • Quantum-Si: Quantum-Si is developing next-generation protein sequencing platforms with single-molecule sensitivity. Comparable to Hyperion as a small-cap next-generation diagnostic platform company focused on ultra-sensitive detection, though Quantum-Si's technology targets proteomics rather than the molecular diagnostics space Helios addresses.
  • Mesa Labs: Mesa Labs develops and manufactures quality assurance instruments and diagnostic tools including biological indicators and sterility assurance products. Comparable to Hyperion in operating as a specialty diagnostic instruments company with B2B sales to manufacturers and clinical end users, though Mesa has a much more diversified product portfolio.

Emerging players

  • Opentrons Labworks: Opentrons provides accessible lab automation and is expanding into diagnostic workflows including COVID testing. Comparable to Hyperion as a smaller player targeting democratization of advanced diagnostics through affordable hardware and software, with some overlap in addressing the OTC and point-of-care testing markets.
  • Paige.AI: Paige applies AI/computer vision to pathology and cancer diagnostics. Comparable to Hyperion in leveraging computer vision and AI to improve diagnostic accuracy beyond what conventional readers achieve, though Paige focuses on digital pathology image interpretation versus Hyperion's assay-result interpretation.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Hyperion Biosystems social profiles

Digital presence

Hyperion Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hyperion Biosystems leadership team

Management profile

Number of profiles

Profiles11 records

Hyperion Biosystems funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hyperion Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyperion Biosystems

What does Hyperion Biosystems do?

Hyperion Biosystems designs and sells diagnostic devices and proprietary software that use computer vision and physics-based, AI-enhanced algorithms to improve the sensitivity and specificity of rapid diagnostic assays. The company partners with leaders in point-of-care and at-home testing markets to integrate its HALO diagnostic reader and algorithm platform into existing diagnostic offerings without requiring assay redesign, while also licensing on-dose anti-counterfeiting authentication technology for pharmaceutical and nutraceutical products.

Is Hyperion Biosystems a public or private company?

Hyperion Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hyperion Biosystems founded?

Hyperion Biosystems was founded in 2013. It employs 11 to 50 people.

Where is Hyperion Biosystems based?

Hyperion Biosystems is headquartered in Watertown, United States, in the North America region.

How does Hyperion Biosystems make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are hardware Sales - HALO Reader and algorithm and Software Services.

Who are Hyperion Biosystems's main competitors?

Broad incumbents on record are BioFire Diagnostics (bioMérieux), Cepheid (Danaher) and GenMark Diagnostics (Roche). Direct peers are Visby Medical, Quanterix, T2 Biosystems, Quantum-Si and Mesa Labs. Emerging players are Opentrons Labworks and Paige.AI.

Does Hyperion Biosystems have an API?

No public API is recorded for Hyperion Biosystems.

What industry is Hyperion Biosystems in?

Hyperion Biosystems's product category is Diagnostic Devices. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireHyperion Biosystems and Colorcon Enter into Licensing Agreement to Commercialize Novel On-Dose Authentication Technology for Pharmaceutical and Nutraceutical IndustriesHyperion Biosystems and Colorcon announced a licensing agreement on May 13, 2025, to commercialize an anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products. This solution integrates advanced authentication measures into dosage forms to combat counterfeit products globally, enhancing security within the pharmaceutical supply chain. The collaboration highlights the ongoing commitment of both companies to innovate and address counterfeiting challenges in their industry.ColorconHyperion Biosystems and Colorcon Enter into Licensing AgreementHyperion Biosystems and Colorcon entered into a licensing agreement to commercialize a joint on-dose authentication technology for pharmaceutical and nutraceutical products. The solution combines Hyperion's AI-enhanced vision systems with Colorcon's taggants to enhance security against counterfeiting within the supply chain.FinSMEsC2Sense Secures $3.2M in Seed Funding - FinSMEsC2Sense, a Cambridge, MA-based digital olfactory platform, raised $3.2M in seed funding led by The Engine. The round included participation from Breakout Labs, Cranberry Capital, and others, with Reed Sturtevant joining the board. Founded in 2014, the company's patented gas-sensing technology detects compounds for applications like food freshness and toxic gas monitoring.TechCrunchMIT researchers develop wearable toxic gas sensorMIT researchers have developed a lightweight wearable toxic gas sensor using carbon nanotubes that can communicate with smartphones via NFC technology to alert users of exposure to dangerous gases like Sarin. The sensor, which weighs less than a credit card and provides irreversible dosage detection, is designed for military personnel on the battlefield and could also be used by refinery workers. The underlying technology has been licensed to C2Sense, a Cambridge-based company, which is working to commercialize the product.